On August 12th, Gelunhui reported that RGC.US fell 12.17% to $11.55 before the opening. The recent trend of this stock has been very active, presenting a volatile situation. During the US stock market session on July 23rd, it once soared more than 860% and closed up 344%, and it also rose nearly 54% last Friday. The company is an early-stage biotechnology company focusing on the research and commercialization of traditional Chinese medicine for the treatment of neurological and cognitive disorders and degenerative changes, especially ADHD and ASD.
美股异动丨脑再生科技盘前跌超12% 上周五曾暴涨54%
US stock market anomaly | Brain regeneration technology fell more than 12% before the market opened, and it had surged by 54% last Friday.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.